Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 3
2014 1
2018 2
2020 1
2021 2
2022 3
2023 2
2024 3
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial.
Couturaud F, Schmidt J, Sanchez O, Ballerie A, Sevestre MA, Meneveau N, Bertoletti L, Connault J, Benhamou Y, Constans J, Quemeneur T, Lapébie FX, Pernod G, Picart G, Elias A, Doutrelon C, Neveux C, Khider L, Roy PM, Zuily S, Falvo N, Lacroix P, Emmerich J, Mahé I, Boileau J, Yaici A, Le Jeune S, Stéphan D, Plissonneau-Duquene P, Ray V, des Déserts MD, Belhadj-Chaidi R, Lamia B, Gruel Y, Presles E, Girard P, Tromeur C, Moustafa F, Rothstein V, Lacut K, Melac S, Barillot S, Mismetti P, Laporte S, Mottier D, Meyer G, Leroyer C; RENOVE Investigators. Couturaud F, et al. Lancet. 2025 Mar 1;405(10480):725-735. doi: 10.1016/S0140-6736(24)02842-3. Lancet. 2025. PMID: 40023651 Free article. Clinical Trial.
Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease.
Burgel PR, Paillasseur JL, Durieu I, Reynaud-Gaubert M, Hamidfar R, Murris-Espin M, Danner-Boucher I, Chiron R, Leroy S, Douvry B, Grenet D, Mely L, Ramel S, Montcouquiol S, Burnet E, Ouaalaya EH, Sogni P, Da Silva J, Martin C; Participating Investigators of the French Cystic Fibrosis Reference Network Study Group. Burgel PR, et al. Ann Am Thorac Soc. 2024 Jul;21(7):1053-1064. doi: 10.1513/AnnalsATS.202312-1065OC. Ann Am Thorac Soc. 2024. PMID: 38579175
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study).
Amari L, Tomasini P, Dantony E, Rousseau-Bussac G, Ricordel C, Bigay-Game L, Arpin D, Morel H, Veillon R, Justeau G, Huchot E, Fournel P, Vergnenegre A, Bizeux A, Subtil F, Clarisse B, Decroisette C, Chouaid C, Greillier L, Bylicki O. Amari L, et al. Among authors: huchot e. Lung Cancer. 2024 Jul;193:107843. doi: 10.1016/j.lungcan.2024.107843. Epub 2024 May 31. Lung Cancer. 2024. PMID: 38830303 Free article. Clinical Trial.
First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018).
Corre R, Decroisette C, Auliac JB, Falchero L, Curcio H, Amrane K, Perol M, Hominal S, Vieillot S, Huchot E, Desage AL, Bernardi M, Veillon R, Doubre H, Bota S, Legarff G, Justeau G, Bylicki O, Roa M, Descourt R, Chouaïd C, Greillier L. Corre R, et al. Among authors: huchot e. Clin Lung Cancer. 2025 Jun;26(4):331-337. doi: 10.1016/j.cllc.2025.03.001. Epub 2025 Mar 4. Clin Lung Cancer. 2025. PMID: 40122771
Coxiella burnetii: A Hidden Pathogen in Interstitial Lung Disease?
Melenotte C, Izaaryene JJ, Gomez C, Delord M, Prudent E, Lepidi H, Mediannikov O, Lacoste M, Djossou F, Mania A, Bernard N, Huchot E, Mège JL, Brégeon F, Raoult D. Melenotte C, et al. Among authors: huchot e. Clin Infect Dis. 2018 Sep 14;67(7):1120-1124. doi: 10.1093/cid/ciy278. Clin Infect Dis. 2018. PMID: 29659760
Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.
Burgel PR, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, Grenet D, Marguet C, Reynaud-Gaubert M, Macey J, Mely L, Fanton A, Quetant S, Lemonnier L, Paillasseur JL, Da Silva J, Martin C; French Cystic Fibrosis Reference Network Study Group. Burgel PR, et al. Am J Respir Crit Care Med. 2021 Jul 1;204(1):64-73. doi: 10.1164/rccm.202011-4153OC. Am J Respir Crit Care Med. 2021. PMID: 33600738
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).
Dhamelincourt E, Descourt R, Rousseau-Bussac G, Doubre H, Decroisette C, Demontrond P, Le Garff G, Falchero L, Huchot E, Vieillot S, Corre R, Kazulinski L, Bizieux A, Bigay-Gamé L, Morel H, Molinier O, Chouaïd C, Guisier F. Dhamelincourt E, et al. Among authors: huchot e. Target Oncol. 2023 Nov;18(6):905-914. doi: 10.1007/s11523-023-01014-z. Epub 2023 Nov 15. Target Oncol. 2023. PMID: 37966566
19 results